Aortic Stenosis.

Similar documents
Aortic Stenosis: UPDATE Anjan Sinha, MD Krannert Institute of Cardiology

Cardiac catheterisation in AS

Congenital. Unicuspid Bicuspid Quadricuspid

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

Aortic Stenosis: Spectrum of Disease, Low Flow/Low Gradient and Variants

Indicator Mild Moderate Severe

Worldwide rheumatic fever is the most common cause of valve disease. In industrialized areas, valvular disease of old age predominates

Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?

The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center

A Health Care Professional s Guide Aortic Stenosis in Seniors

Valvular heart disease : Role of medication ( drug and intervention ) Pol.Col.Dr.Kasem Ratanasumawong

Severe Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative

Low Gradient Severe? AS

ECHO HAWAII. Role of Stress Echo in Valvular Heart Disease. Not only ischemia! Cardiomyopathy. Prosthetic Valve. Diastolic Dysfunction

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

Management of significant asymptomatic aortic stenosis. Alec Vahanian Bichat Hospital University Paris VII Paris, France

The production of murmurs is due to 3 main factors:

Structural Heart Disease Transcatheter Aortic Valve Replacement (TAVR)

Managing the Low Output Low Gradient Aortic Stenosis Patient

The production of murmurs is due to 3 main factors:

TAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:

Valvular Guidelines: The Past, the Present, the Future

TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con

Ejection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.

Asymptomatic Valvular Disease:

Valvular Heart Disease

2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR

Hypertension in Aortic Valve Disease

Ejection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.

Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC

Andrzej Ochala, MD Medical University of Silesia, Katowice, Poland

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)

Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School

A new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center

Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data

TAVR: Echo Measurements Pre, Post And Intra Procedure

Assessment and Preparation of Patients with TAVI. Rob Tanzola Associate Professor, Queen s University

Role of Stress Echo in Valvular Heart Disease. Satoshi Nakatani Osaka University Graduate School of Medicine Osaka, Japan

«Paradoxical» low-flow, low-gradient AS with preserved LV function: A Silent Killer

Stage of Valvular AS. Outline 10/14/16. Low-flow and Other Challenges to the Assessment of Aortic Stenosis. Severe AS

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

TSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD

Spotlight on Valvular Heart Disease Guidelines

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved

New Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor. Cardiothoracic Radiology

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40

Valve Disease in the Pregnant Patient

Aortic valve disease. Acknowledgement for slides. Heart Valves 4/28/2018. Adopted from

Welcome 17 Michigan TAVR Participating Hospitals!

SONOGRAPHER & NURSE LED VALVE CLINICS

TAVR SPRING 2017 The evolution of TAVR

Section V VALVULAR HEART T DISEASE. Chapter 27 Aortic Stenosis Chapter 28 Aortic Insufficiency Chapter 29 Mitral Valve Disease...

DOPPLER HEMODYNAMICS (1) QUANTIFICATION OF PRESSURE GRADIENTS and INTRACARDIAC PRESSURES

NY STATE NPA 33 rd Annual Conference TAVR & Structural Heart Update

Natural History and Echo Evaluation of Aortic Stenosis

Aortic Stenosis: Background

Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?

Case Presentations TAVR: The Good Bad and The Ugly

MITRAL STENOSIS: MANY FLAVORS Rheumatic and Calcification. Rheumatic Mitral Stenosis 76yo male

Cardiology. the Sounds: #7 HCM. LV Outflow Obstruction: Aortic Stenosis. (Coming Soon - HCM)

n S2=Aortic valve closure, pulmonic n S3=Very healthy or very sick LV n Children and young athletes, CHF n S4=Stiff LV, incr LVEDP, HTN, hypertrophy

Dr.ssa Loredana Iannetta. Centro Cardiologico Monzino

Imaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013

Low Gradient Severe AS: Who Qualifies for TAVR? Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor

Aortic stenosis and regurgitation

TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH

Comprehensive Echo Assessment of Aortic Stenosis

LV geometric and functional changes in VHD: How to assess? Mi-Seung Shin M.D., Ph.D. Gachon University Gil Hospital

Aortic stenosis aetiology: morphology of calcific AS,

Aortic Regurgitation & Aorta Evaluation

Valvular Heart Disease. Dr. HANAN ALBACKR

TAVR: Intermediate Risk Patients

Aortic regurgitation and aneurysm. epidemiology and guidelines

Aortic Stenosis Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan

AORTIC AND MITRAL VALVE DISEASE HEMODYNAMICS AND CLINICAL ASPECTS

Nothing to Disclose. Questions. Disclosure Asymptomatic Severe Aortic Stenosis: (When) Should One Intervene? Paul Wood at the Nathanson Lecture, 1958

Valvular Stenosis and Regurgitation: Barriers to Flow

Valvular Heart Disease: Assessment and Timing of Intervention. Graham Cole Consultant Cardiologist Imperial College Healthcare NHS Trust

Journal of the American College of Cardiology Vol. 44, No. 9, by the American College of Cardiology Foundation ISSN /04/$30.

Echocardiographic Evaluation of Aortic Valve Prosthesis

Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?

How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min

Index of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125

Disclosures. LGH TAVR: Presentation Outline 2/2/2016. Updates in Transcatheter Aortic Valve Replacement (TAVR) and the LGH Experience

Valvular Heart Disease Transcatheter Valve Therapies. October 2016 Brian Whisenant MD

Review of Cardiac Mechanics & Pharmacology 10/23/2016. Brent Dunworth, CRNA, MSN, MBA 1. Learning Objectives

Aortic Valvular Stenosis

Incidence And Predictors Of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation

TAVR in 2020: What is Next!!!!

Adult Cardiac Surgery

TAVR IN INTERMEDIATE-RISK PATIENTS

Valvular Heart Disease: Recognition and Management in the Outpatient Setting

Extension to medium and low risk patients? Friedrich Eckstein University Hospital Basel

Which one of the following echocardiographic profiles most strongly indicates the need for aortic valve replacement? FS [

Management of Difficult Aortic Root, Old and New solutions

Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update

Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients

Mitral Valve Disease. Prof. Sirchak Yelizaveta Stepanovna

PARAVALVULAR LEAK POST TAVR. Elements of Follow-up Post TAVR

Transcription:

Aortic Stenosis www.cardiconcept.com

Common causes Normal Rheumatic (Rim or Commissures) Calcific Degenerative Bicuspid Adapted from C. Otto, Principles of Echocardiography, 2007

Rare causes Congenital Aortic stenosis Severe artherosclerosis of aorta and aortic valve (In Hyperlipoproteinemia type II) Rheumatoid arthritis with aortic valve involvement

Aortic disease Bicuspid aortic valve Fish mouth opening

Distribution by age group of BAV versus TAV In patients undergoing AVR for aortic stenosis. TAV BAV Age Circulation 2005;111: 920-925

Aortic disease Calcific Aortic Valve Disease Aortic Stenosis VS Aortic Sclerosis Paget s disease Age-related calcific Genetic polymorphism ESRD CV risks factor (DM, HT, LDL,smoking)

Aortic Stenosis Aortic Sclerosis Defined as calcification and thickening of the aortic valve without significant outflow obstruction (gradient < 20 to 25 mmhg)

Aortic disease Calcific Aortic Valve Disease Can Statins Slow progression of disease? SEAS study(n 1800) ASTONOMER study(n 269) Simvastatin + Ezetimibe VS Placebo Rosuvastatin VS Placebo No Statistically Significant (Mortality, time to AVR)

Rheumatic Aortic Stenosis Developing Country Frequently combined AS + AR Usually combined with Rheumatic Mitral Valve Involvement

Pathophysiology AS LV outflow obstruction LV systolic P LV EjectionTime LV diastolic P Aortic P LV mass O2 consumption Blood supply ischemia LV failure & myocardial ischemia

Aortic pressure gradient & AVA correlation S Severe : Remember : 4-40 (Vmax 4 m/sec, AV mean PG 40 mmhg) AVA 1.0 cm2 Moderate : (Vmax 3-4 m/sec, AV mean PG 20-40 mmhg) AVA 1.0-1.5 cm2

European Heart Journal Jul 2013, 34 (25) 1906-1914 Aortic pressure gradient & AVA correlation AV mean PG 20 mmhg correlate with AVA 1.0 cm2 AV mean PG 40 mmhg correlate with AVA 0.8 cm2

Hemodynamic SBP LV diameter 2 LV wall thickness LV wall stress

Ejection fraction and wall stress relationship EF & LV wall stress are correlate and predictable If not Poor outcome Carabello BA, Green LH, Grossman W, et al: Hemodynamic determinants of prognosis of aortic valve replacement in critical aortic stenosis and advanced congestive heart failure. Circulation 1980;62: 42-48.

Hemodynamic LA pressure Atrial fibrillation LVEDP

Hemodynamic Heart rate Systolic ejection time Cardiac output in response to exercise Rise in blood pressure < 10 mmhg (Severe obstruction)

Hemodynamic High LVEDP & Low Aortic Pressure P P Subendocardium Myocardial Ischemia

Clinical manifestation Dyspnea on exertion Angina 5 yrs. Syncope 3 yrs. Heart failure 2 yrs. Bicuspid AS onset 50-70 year-old Tricuspid AS > 70 year-old

Heydes syndrome Aortic stenosis + LGIB (Angiodysplasia : most common Rt. side colon)

Physical examination Pulsus parvus et tardus Severity SEM radiate to neck Gallavardin phenomenon Single S2 or paradoxical S2

Physical examination Heavy calcified and immobility A2 delayed closure (esp. LBBB) S2 Single S2 or Paradoxical split S2 S1 A2 P2 S4 due to LV stiffness S1 A2 P2

Dynamic Auscultation Aortic Stenosis All soft Valsava ( Decrease Preload Decrease aortic blood flow) Hand grip ( Increase afterload Decrease aortic blood flow)

ECG

CXR Poststenotic dilatation Roundening of apex

Prognosis Asymptomatic Gradient Prognosis Hemodynamic progression AVA -0.12 cm2/year AV Vmax 0.32 m/sec/year AV mean PG 7 mmhg/year <3.0 m/s 3.0-4.0 m/s > 4.0 m/s

Classification of Aortic stenosis severity based on ACC/AHA guideline

Classification of Aortic stenosis severity based on ACC/AHA guideline

Progression from Aortic sclerosis Severe aortic stenosis Mean about 7 years Arch Intern Med. 2002;162(20):2345-2347.

From Unicuspid to Quadricuspid Unicuspid Bicuspid Tricuspid Quadricuspid Associate with AS Associate with AR>AS Associate with AR

Unicuspid Unicommissural Acommissural a lateral attachment of the valve orifice to the aorta estimated incidence of 0.02% eccentric teardrop opening may also be associated with dilation of the ascending aorta.

Bicuspid AV and Aortic root dilatation (Aortopathy + flow disturbance)

Patterns of bicuspid aortopathy TYPE 1 Dilatation of tubular ascending aorta primarily along convexity of aorta, with mild to moderate root dilatation RCC-LCC fusion TYPE 2 Arch dilatation with involvment of tubular ascending aorta, with relative sparing of root RCC-NCC fusion TYPE 3 Isolated aortic root involvment with normal tubular ascending aorta and arch dimensions Younger age & genetic

Bicuspid AV and Coarctation of aorta 10% 50% Bicuspid AV 10% Coarctation of aorta Coarctation of aorta 50% Bicuspid AV

Savino K, Quintavalle E, Ambrosio G. Quadricuspid aortic valve: A case report and review of the literature. J Cardiovasc Echography 2015;25:72-6 Quadricuspid subtype Most common

Medical management and Follow up Mild AS F/U echo q 3-5 years Moderate AS F/U echo q 1-2 year(s) Rx Systemic hypertension Diuretics use with caution (may cause hypotension) ACEI should be used with caution in LV systolic dysfunction. Avoid Betablocker (worsening LV function)

Management in critical AS Vasodilator Nitroprusside (decrease afterload) Inotropic agent Preload optimization Atrial arrhythmia Abrupt decompensation Cardioversion is recommended

Nishimura et al. JACC Vol. 63, No. 22, 2014 2014 AHA/ACC Valvular Heart Disease Guideline Summary of Recommendations for AS: Timing of Intervention

Low flow Low gradient AS Calcium score > 1650 Lack of contractile reserve has been associated with lower operative survival rate (6% vs. 33% ) Circulation: Cardiovascular Imaging.2014; 7: 545-551

The relationship between transvalvular flow and transvalvular gradient Am Heart J 1951;41: 1-29

Balloon valvulotomy Acute hemodynamic effect 50% gradient reduction AVA increase 0.2-0.3 cm2 In hospital Mortality rate 10% Pre PBAV Post PBAV No benefit long term outcome N Engl J Med. 1991; 325: 17 23. Circulation. 1991; 84: 2383 2397. J Intervent Cardiol. 2006; 19( 3): 269 275. J Am Coll Cardiol. 1995; 26( 6): 1522 1528.

TAVR (Transcatheter aortic valve replacement) SAPIEN CoreValve

PARTNER (Placement of AoRtic TraNscathetER valves) F/U 2 yrs. F/U 2 yrs. Cohort A : High risk but operable N Engl J Med 2011; 364:2187-2198 Cohort B : Inoperable N Engl J Med 2010; 363:1597-1607

PARTNER (Placement of AoRtic TraNscathetER valves) Death from any cause or stroke Death from any cause Cohort A : High risk but operable N Engl J Med 2011; 364:2187-2198 Cohort B : Inoperable 40% RRR N Engl J Med 2010; 363:1597-1607

PARTNER (Placement of AoRtic TraNscathetER valves) Atrial fibrillation, Bleeding SAVR > TAVR Vascular complication, Stroke or TIA TAVR > SAVR N Engl J Med 2011; 364:2187-2198

PARTNER 2 Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients Symptomatic Severe AS (N=2032),mean age 81 ±6.7 yo. STS 4 and 10 (mean 5.8) Assessment by Heart Valve team Intermediate risk for AVR Inoperable Y Transfemoral access? Transfemoral Transapical N Y Transfemoral access? N 1:1 Randomization 1:1 Randomization Not in study TAVR (Sapien XT) Surgical AVR TAVR (Sapien XT) TAVR Sapien Primary Outcome : All Cause Mortality+Major Stroke at 2 year (Non-inferiority) Primary Outcome : All Cause Mortality+Major Stroke at 1 year (Non-inferiority)

PARTNER 2 Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients N Engl J Med 2016; 374:1609-1620

PARTNER 2 (Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients ) Atrial fibrillation, Major Bleeding SAVR > TAVR Vascular complication, TIA TAVR > SAVR N Engl J Med 2016; 374:1609-1620

Recommendations for AS: Surgical AVR or TAVR Nishimura et al. JACC Vol. 63, No. 22, 2014 2014 AHA/ACC Valvular Heart Disease Guideline

Surgical AVR

Estimates of freedom from structural valve deterioration (SVD) for patients undergoing porcine aortic valve Slower valve deterioration in elderly Cohn LH, Collins JJ Jr, Rizzo RJ, et al: Twenty-year follow-up of the Hancock modified orifice porcine aortic valve. Ann Thorac Surg 66:S30, 1998

Summary of Recommendations for Prosthetic Valve Choice Bioprosthetic (if anticoagulant is contraindicated) (I) Mechanical valve (IIa) Ross procedure (IIb) Bioprosthetic or Mechanical (IIa) Bioprosthetic (IIa) 60 year 70 year

Ross Procedure

Hemodynamic in Aortic stenosis

Gorlin formula Flow across the valve Constant x PG AVA = CO x 1000 / (systolic time x HR) 43.3 x AV mean PG MVA = CO x 1000 / (diastolic time x HR) 37.7 x MV mean PG

Pressure gradient in AS Ao LV Peak to peak gradient = 70% of Peak instantaneous gradient

AS VS HOCM

Pressure recovery phenomenon Echocardiography may over estimate true gradient Aortic root size < 3 cm Pressure recovery (small aortic root size)

Pressure Volume Loop

Hypertension and Aortic Stenosis Trojan Horse (Blood flow) Ejection flow Gate (Aortic stenosis) Resistance Army (Hypertension) Resistance Systemic hypertension Change in transvalvular flow decrease aortic valve area Jen s J. Kaden, Dariusch Haghi Hypertension in aortic valve stenosis a Trojan horse European Heart Journal Jun 2008,

References

Thankyou